HIV drug resistance
The ability of HIV to mutate and reproduce itself in the presence of antiretroviral drugs is called HIV drug resistance (HIVDR). The consequences of HIVDR include treatment failure, need to start more costly second- and third- line treatments, increased health costs associated with these, spread of drug resistant HIV, and need to develop new anti-HIV drugs.
WHO, and its partner organizations and experts of HIVResNet group have developed a Global strategy for the surveillance and monitoring of HIV drug resistance. The strategy generates data on the emergence and transmission of HIVDR and equips countries with information to select first and second line antiretroviral therapy regimens.
Revised concept notes for the surveillance of pre-treatment and acquired HIV drug resistance were launched at the WHO HIV Res Net meeting on 2 March 2014. These concept notes replace older versions and assess drug resistance in populations starting and receiving antiretroviral therapy.
HIV drug resistance surveillance in children less than 18 months newly diagnosed with HIV in Zimbabwe
- WHO HIV drug resistance steering group meeting
- Implementation & sustainability of HIV drug resistance surveillance in Africa Addis Ababa, Ethiopia
- Implementation & sustainability of HIV drug resistance surveillance in Africa Cape Town, South Africa